These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A prospective study of Autologous Growth Factors (AGF) in lumbar interbody fusion. Jenis LG; Banco RJ; Kwon B Spine J; 2006; 6(1):14-20. PubMed ID: 16413442 [TBL] [Abstract][Full Text] [Related]
3. Use of autologous growth factors in lumbar spinal fusion. Lowery GL; Kulkarni S; Pennisi AE Bone; 1999 Aug; 25(2 Suppl):47S-50S. PubMed ID: 10458274 [TBL] [Abstract][Full Text] [Related]
4. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Carreon LY; Glassman SD; Anekstein Y; Puno RM Spine (Phila Pa 1976); 2005 May; 30(9):E243-6; discussion E247. PubMed ID: 15864142 [TBL] [Abstract][Full Text] [Related]
5. Role of activated growth factors in lumbar spinal fusions. Castro FP J Spinal Disord Tech; 2004 Oct; 17(5):380-4. PubMed ID: 15385877 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of autologous growth factors in lumbar intertransverse fusions. Weiner BK; Walker M Spine (Phila Pa 1976); 2003 Sep; 28(17):1968-70; discussion 1971. PubMed ID: 12973143 [TBL] [Abstract][Full Text] [Related]
7. Pseudarthrosis and Rod Fracture Rates After Transforaminal Lumbar Interbody Fusion at the Caudal Levels of Long Constructs for Adult Spinal Deformity Surgery. Dinizo M; Srisanguan K; Dolgalev I; Errico TJ; Raman T World Neurosurg; 2021 Nov; 155():e605-e611. PubMed ID: 34474159 [TBL] [Abstract][Full Text] [Related]
8. Minimally invasive transforaminal lumbar interbody fusion with expandable versus static interbody devices: radiographic assessment of sagittal segmental and pelvic parameters. Hawasli AH; Khalifeh JM; Chatrath A; Yarbrough CK; Ray WZ Neurosurg Focus; 2017 Aug; 43(2):E10. PubMed ID: 28760032 [TBL] [Abstract][Full Text] [Related]
9. Increased incidence of pseudarthrosis after unilateral instrumented transforaminal lumbar interbody fusion in patients with lumbar spondylosis: Clinical article. Gologorsky Y; Skovrlj B; Steinberger J; Moore M; Arginteanu M; Moore F; Steinberger A J Neurosurg Spine; 2014 Oct; 21(4):601-7. PubMed ID: 25084031 [TBL] [Abstract][Full Text] [Related]
10. The effects of local insulin application to lumbar spinal fusions in a rat model. Koerner JD; Yalamanchili P; Munoz W; Uko L; Chaudhary SB; Lin SS; Vives MJ Spine J; 2013 Jan; 13(1):22-31. PubMed ID: 23295034 [TBL] [Abstract][Full Text] [Related]
11. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity. Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280 [TBL] [Abstract][Full Text] [Related]
12. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up. Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Lumbosacral Fusion Grade in Patients after Transforaminal and Anterior Lumbar Interbody Fusion with Minimum 2-Year Follow-Up. Liu J; Xie R; Chin CT; Rajagopalan P; Duan PG; Li B; Burch S; Berven SH; Mummaneni PV; Chou D Orthop Surg; 2023 Sep; 15(9):2334-2341. PubMed ID: 37526121 [TBL] [Abstract][Full Text] [Related]
14. Radiographic Appearance of Transforaminal Lumbar Interbody Fusion Performed With and Without Recombinant Human Morphogenetic Protein-2. Stensby JD; Kaliney RW; Alford B; Shen FH; Patrie JT; Fox MG AJR Am J Roentgenol; 2016 Mar; 206(3):588-94. PubMed ID: 26901016 [TBL] [Abstract][Full Text] [Related]
16. Bone graft gel: autologous growth factors used with autograft bone for lumbar spine fusions. Bose B; Balzarini MA Adv Ther; 2002; 19(4):170-5. PubMed ID: 12431042 [TBL] [Abstract][Full Text] [Related]
17. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients. Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111 [TBL] [Abstract][Full Text] [Related]
18. Role of Weekly Teriparatide Administration in Osseous Union Enhancement within Six Months After Posterior or Transforaminal Lumbar Interbody Fusion for Osteoporosis-Associated Lumbar Degenerative Disorders: A Multicenter, Prospective Randomized Study. Ebata S; Takahashi J; Hasegawa T; Mukaiyama K; Isogai Y; Ohba T; Shibata Y; Ojima T; Yamagata Z; Matsuyama Y; Haro H J Bone Joint Surg Am; 2017 Mar; 99(5):365-372. PubMed ID: 28244906 [TBL] [Abstract][Full Text] [Related]
19. Lateral lumbar interbody fusion: clinical and radiographic outcomes at 1 year: a preliminary report. Sharma AK; Kepler CK; Girardi FP; Cammisa FP; Huang RC; Sama AA J Spinal Disord Tech; 2011 Jun; 24(4):242-50. PubMed ID: 20844451 [TBL] [Abstract][Full Text] [Related]
20. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Pradhan BB; Bae HW; Dawson EG; Patel VV; Delamarter RB Spine (Phila Pa 1976); 2006 May; 31(10):E277-84. PubMed ID: 16648733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]